Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | DHPS | P49366 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4711596 | 0.89 | DCUN1D1 (0.45) | TP53NR1H2NR1H3DCUN1D1ADORA2A | |
| SCHEMBL4713814 | 0.88 | ADORA2A (0.50) | TP53NR1H2NR1H3DCUN1D1ADORA2A | |
| SCHEMBL4711451 | 0.88 | PDE3B (0.49) | TP53GAAKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL4714832 | 0.82 | CHEK1 (0.46) | KDM4ESMN1; SMN2HSD17B10PDGFRBPDGFRA | |
| SCHEMBL4713601 | 0.81 | BCHE (0.47) | NR1H2NR1H3ADORA2AKDM4EHTT | |
| SCHEMBL5246987 | 0.79 | PDE4A (0.59) | KDM4ESMN1; SMN2HSD17B10ADORA1PDGFRB | |
| SCHEMBL5247087 | 0.78 | KDM4E (0.40) | NR1H2NR1H3DCUN1D1ADORA2AKDM4E | |
| SCHEMBL5246387 | 0.76 | SMN1; SMN2 (0.40) | TP53GAAKDM4EHTTSMN1; SMN2 | |
| SCHEMBL5246390 | 0.74 | HSD17B10 (0.42) | GAAKDM4EHTTSMN1; SMN2HSD17B10 | |
| SCHEMBL5250936 | 0.74 | CRHR1 (0.54) | TP53ADORA2AGAAKDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1519934-B1 | PYRAZOLOISOQUINOLINE DERIVATIVES FOR INHIBITING NF$G(K)B-INDUCING KINASE (NIK) | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-09-19 | — | — | EP | claimed |
| US-6841556-B2 | Pyrazoloisoquinoline derivatives for inhibiting NFκB-inducing kinase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-11 | — | — | US | claimed |
| US-20040097541-A1 | Pyrazoloisoquinoline derivatives for inhibiting NFkappaB-inducing kinase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-05-20 | — | — | US | claimed |
| WO-2004005287-A9 | PYRAZOLOISOQUINOLINE DERIVATIVES FOR INHIBITING NFKAPPAB-INDUCING KINASE (NIK) | AVENTIS PHARMA GMBH (DE) | 2004-03-04 | — | — | WO | claimed |
| EP-1519934-B1 | PYRAZOLOISOQUINOLINE DERIVATIVES FOR INHIBITING NF$G(K)B-INDUCING KINASE (NIK) | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-09-19 | — | — | EP | disclosed |
| US-7132428-B2 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-20050009859-A1 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-01-13 | — | — | US | disclosed |
| US-6841556-B2 | Pyrazoloisoquinoline derivatives for inhibiting NFκB-inducing kinase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-11 | — | — | US | disclosed |
| US-20040097541-A1 | Pyrazoloisoquinoline derivatives for inhibiting NFkappaB-inducing kinase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-05-20 | — | — | US | disclosed |
| WO-2004005287-A9 | PYRAZOLOISOQUINOLINE DERIVATIVES FOR INHIBITING NFKAPPAB-INDUCING KINASE (NIK) | AVENTIS PHARMA GMBH (DE) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097541-A1 | Pyrazoloisoquinoline derivatives for inhibiting NFkappaB-inducing kinase | NFKBIA, IKBKB, IKBKG | TP53 1059/4885NR1H2 197/4885NR1H3 247/4885 |
| US-20050009859-A1 | Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders | PRKDC, MAP3K2, MAP3K20 | TP53 587/4885NR1H2 458/4885NR1H3 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.